Danon disease presenting with dilated cardiomyopathy and a complex phenotype.
Matthew R G MR Taylor,
Lisa L Ku,
Dobromir D Slavov,
Jean J Cavanaugh,
Mark M Boucek,
Xiao X Zhu,
Sharon S Graw,
Elisa E Carniel,
Carl C Barnes,
Dianna D Quan,
Ryan R Prall,
Mark A MA Lovell,
Gary G Mierau,
Patsy P Ruegg,
Naresh N Mandava,
Michael R MR Bristow,
Jeffrey A JA Towbin,
Luisa L Mestroni and
J Hum Genet 52(10):830-5 (2007)
PMID 17899313
X-linked dilated cardiomyopathy (XLCM) was first described in 1987 and associated with dystrophin gene (DMD) mutations a decade later in one of the original two families. Here we report long-term follow-up of the second family (XLCM-2), for which a DMD mutation was never found. Analysis of the lysosome-associated membrane protein-2 (LAMP-2) gene detected a novel mutation, confirming a diagnosis of Danon disease. The broad phenotype in this family included dilated and hypertrophic cardiomyopathy, cardiac pre-excitation, skeletal myopathy with high serum creatinine kinase, cognitive impairement (in males), and and a pigmentary retinopathy in affected females. Cardiac biopsy in a 13-month-old mutation-carrying male showed no vacuolization by standard histology. We conclude that XLCM may be the presenting sign of Danon disease and, in the presence of familial history of HCM, pre-excitation, skeletal muscle involvement and retinal pigmentary dystrophy should prompt LAMP-2 clinical testing. Furthermore, the absence of vacuolar myopathy in biopsies from young patients may not exclude Danon disease.
DOI: 10.1007/s10038-007-0184-8
Version: za2963e q8za9 q8zb2 q8zcf q8zd8 q8ze7 q8zf6 q8zga
Viewers of this paper also looked at these papers: